Ongoing support is critical for effective diabetes (DM) self-management, but difficult to deliver, particularly in areas with limited resources. The purpose of the study was to assess the impact of a virtual support model on DM outcomes for high-risk patients in rural underserved communities.

Methods: Patients with HbA1c>9% receiving care in federally qualified centers were referred to the Telemedicine for Reach, Education, Access, Treatment and Ongoing Support (TREAT-ON) program, where a Diabetes Care and Education Specialist (DCES) provided in person diabetes self-management education and ongoing support through videoconferencing. Participant demographics, BMI and HbA1c were collected from patient records. Participants completed the DM Summary of Self-Care Activities, Distress and Empowerment Scales and Morisky Medication Adherence Measure at baseline and 6 months, and the Telehealth Usability Questionnaire at study completion. Pre/post values were compared for HbA1c, self-care, psychosocial and process outcomes.

Results: Participants (n=37) were 84% white, mean age 46.1 years with mean BMI 37.5. Glycemia improved with a mean reduction in HbA1c from 11.2% at baseline to 9.1% at follow-up (p<.001) . There was significant improvement in self-care behaviors of general diet (p=.001) and foot care (p=.041) . DM distress was reduced significantly (p<.001) , attributed to less emotional and regimen distress. Participants also reported a high level of satisfaction with TREAT-ON and interest in future use (4.6/5 points) .

Conclusions: Findings offer evidence of significant benefits and acceptability of a video-conferencing delivery model for DM self-management support. Future research should explore additional ways to empower individuals to continue and sustain improvements.


R.Hammoudeh: None. J.S.Krall: Research Support; Becton, Dickinson and Company, Sanofi. P.A.Johnson: None. S.L.Reynolds: None. K.Ruppert: None. J.Ng: Research Support; Sanofi. L.M.Siminerio: Advisory Panel; Abbott, Bayer AG, Research Support; Becton, Dickinson and Company, Sanofi.


National Institute of Diabetes Digestive and Kidney Diseases of the National Institutes of Health (R34DK123370) .

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at